Ashvattha Therapeutics Announces Collaboration with Stanford University for Preclinical Development of a Novel Neuroimaging Agent, OP-801
Ashvattha initiates a preclinical proof of concept study for OP-801 imaging of neuroinflammation. This Investigational New Drug (IND)-enabling research will be conducted in collaboration with a team of researchers at the Stanford University School of Medicine led by Michelle James, Ph.D., Assistant Professor of Radiology and Neurology.